Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Rhea-AI Summary

Longeveron (NASDAQ: LGVN) will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025 in New York.

Management will hold one-on-one investor meetings during the conference to discuss the company's clinical-stage cellular therapy programs for rare pediatric and aging-related conditions.

News Market Reaction – LGVN

+0.28%

+0.28% Session close to close

In the Oct 6 session, LGVN gained 0.28%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the 4^th Annual ROTH Healthcare Opportunities Conference.

Longeveron management will host one-on-one meetings with investors at the conference to be held October 9, 2025 in New York.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions 
derek.cole@iradvisory.com

FAQ

When will Longeveron (LGVN) attend the ROTH Healthcare Opportunities Conference?

Longeveron will participate on October 9, 2025 in New York.

Will Longeveron (LGVN) meet with investors at the ROTH conference?

Yes. Longeveron management will host one-on-one investor meetings at the conference.

What topics will Longeveron (LGVN) likely cover at the October 9, 2025 conference?

Management is expected to discuss its clinical-stage cellular therapy programs for rare pediatric and aging-related conditions.

How can investors request a meeting with Longeveron (LGVN) at the ROTH conference?

Investors should contact Longeveron's investor relations or conference organizers to request one-on-one meeting availability.

Where is the 4th Annual ROTH Healthcare Opportunities Conference being held for LGVN's participation?

The conference is scheduled to be held in New York on October 9, 2025.